1
|
Song L, Li B, Wu H, Wu C, Zhang X. Understanding the factors of wearable devices among the patients with thyroid cancer: A modified UTAUT2 model. PLoS One 2024; 19:e0305944. [PMID: 39058689 PMCID: PMC11280220 DOI: 10.1371/journal.pone.0305944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 06/08/2024] [Indexed: 07/28/2024] Open
Abstract
Wearable devices hold promising prospects on a global scale, including in China. Thyroid cancer prevalence is notably high in China.This purpose of this researchwas to provide an updated theoretical model for assessing Chinese thyroid cancer patients' intentions towards wearable devices, based on the UTAUT2 framework, and to ascertain the factors that have an impact on these intents. A cross-sectional study with an institutional focus wasconducted from January 20, 2023, to June 30, 2023, at several general hospitals in China. Five hundred participants were recruited to identify predictors of wearable device use.The questionnaire survey about patients' intentionswas collected using a face-to-face method, employing a random sampling technique for patient selection. Four hundred sixty-nine individuals (93.8%) had the intention to use wearable devices. The intentions were highly impacted by performance expectancy (PE), effort expectancy (EE), social influence (SI), hedonic motivation (HM), price value (PV) and habit (HA). Usage intention (UI)was a statistically predictor of Usage behavior (UB). The facilitating condition(FC) was not significant. Gender positively moderated the relationship between EE and UI. Income positively moderated the relationship between all variables and UI.Overall, the utilization of wearable devices among patients diagnosed with thyroid cancer has demonstrated considerable potential. This study offers a series of suggestions for digital health developers,healthcare decision-makers,doctors and patients.
Collapse
Affiliation(s)
- LingLi Song
- Department of Clinical Laboratory, Associated Hospital, Beihua University, Jilin, China
| | - BinXian Li
- Department of Clinical Laboratory, Associated Hospital, Beihua University, Jilin, China
| | - HaiBo Wu
- Department of Clinical Laboratory, Associated Hospital, Beihua University, Jilin, China
| | - CuiCui Wu
- Department of Clinical Laboratory, Associated Hospital, Beihua University, Jilin, China
| | - XueQi Zhang
- Department of Nuclear Medicine, Associated Hospital, Beihua University, Jilin, China
| |
Collapse
|
2
|
Cloß K, Verket M, Müller-Wieland D, Marx N, Schuett K, Jost E, Crysandt M, Beier F, Brümmendorf TH, Kobbe G, Brandts J, Jacobsen M. Application of wearables for remote monitoring of oncology patients: A scoping review. Digit Health 2024; 10:20552076241233998. [PMID: 38481796 PMCID: PMC10933580 DOI: 10.1177/20552076241233998] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2025] Open
Abstract
Objective This review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation. Methods A Medline, Embase and clinicaltrials.gov search identified journal articles, conference abstracts, letters, reports, dissertations and registered studies on the use of wearables in patients with malignancies published up to 10 November 2021. Results Of 2509 records identified, 112 met the eligibility criteria. Of these, 9.8% (11/112) were RCTs and 47.3% (53/112) of publications were observational. Wearables were investigated pre-treatment (2.7%; 3/112), during treatment (34.8%; 39/112), post-treatment (17.9%; 20/112), in survivors (27.7%; 31/112) and in non-specified or multiple treatment phases (17.0%; 19/112). Medical-grade wearables were applied in 22.3% (25/112) of publications. Primary objectives ranged from technical feasibility (8.0%; 9/112), user feasibility (42.9%; 48/112) and correlational analysis (40.2%; 45/112) to outcome change analysis (8.9%; 10/112). Outcome change was mostly investigated regarding physical activity improvement (80.0%; 8/10). Most publications (42.9%; 48/112) and registered studies (39.3%; 24/61) featured multiple cancer types, with breast cancer as the most prevalent specific type (22.3% in publications, 16.4% in registered studies). Conclusions Most studies among oncology patients using wearables are focused on assessing the user feasibility of consumer-grade wearables, whereas rates of RCTs assessing clinical efficacy are low. Substantial improvements in clinically relevant endpoints by the use of wearables, such as morbidity and mortality are yet to be demonstrated.
Collapse
Affiliation(s)
- Katharina Cloß
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Marlo Verket
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Dirk Müller-Wieland
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Nikolaus Marx
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Katharina Schuett
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Edgar Jost
- Department of Internal Medicine IV, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
| | - Martina Crysandt
- Department of Internal Medicine IV, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
| | - Fabian Beier
- Department of Internal Medicine IV, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
| | - Tim H Brümmendorf
- Department of Internal Medicine IV, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
| | - Guido Kobbe
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Julia Brandts
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
- Imperial Centre for Cardiovascular Disease Prevention (ICCP), Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK
| | - Malte Jacobsen
- Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany
| |
Collapse
|